These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1362267)

  • 21. Activation of 5-HT3 receptors enhances the electrically evoked release of [3H]noradrenaline in rat brain limbic structures.
    Mongeau R; De Montigny C; Blier P
    Eur J Pharmacol; 1994 May; 256(3):269-79. PubMed ID: 8045271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different effects of tropisetron and ondansetron in learning and memory paradigms.
    Pitsikas N; Borsini F
    Pharmacol Biochem Behav; 1997 Apr; 56(4):571-6. PubMed ID: 9130279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists.
    Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2001 May; 420(2-3):113-7. PubMed ID: 11408032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Serotonin (5-HT)3 receptors: antagonists and their pharmacological profiles].
    Miyata K; Honda K
    Nihon Yakurigaku Zasshi; 1994 Sep; 104(3):143-52. PubMed ID: 7959407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model.
    Roychoudhury M; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 1997 Mar; 19(2):107-11. PubMed ID: 9151286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clozapine's antipsychotic effects do not depend on blockade of 5-HT3 receptors.
    Squires RF; Saederup E
    Neurochem Res; 1999 May; 24(5):659-67. PubMed ID: 10344595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-HT3 receptors.
    Costall B; Naylor RJ
    Curr Drug Targets CNS Neurol Disord; 2004 Feb; 3(1):27-37. PubMed ID: 14965242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Central action of 5-HT3 receptor ligands in the regulation of sleep-wakefulness and raphe neuronal activity in the rat.
    Adrien J; Tissier MH; Lanfumey L; Haj-Dahmane S; Jolas T; Franc B; Hamon M
    Neuropharmacology; 1992 Jun; 31(6):519-29. PubMed ID: 1407392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-HT(3) receptor antagonists and anxiety; a preclinical and clinical review.
    Olivier B; van Wijngaarden I; Soudijn W
    Eur Neuropsychopharmacol; 2000 Mar; 10(2):77-95. PubMed ID: 10706989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin receptor and reuptake sites: pharmacologic significance.
    Gonzalez-Heydrich J; Peroutka SJ
    J Clin Psychiatry; 1990 Apr; 51 Suppl():5-12; discussion 13. PubMed ID: 2157701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity.
    Alvarez-Guerra M; d'Alché-Birée F; Wolf WA; Vargas F; Dib M; Garay RP
    Psychopharmacology (Berl); 2000 Jan; 147(4):412-7. PubMed ID: 10672635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [An outline of 5-HT3 receptor antagonists (1)--In pharmacological actions].
    Tsukagoshi S; Ohta J; Taguchi T
    Gan To Kagaku Ryoho; 1993 Nov; 20(14):2108-14. PubMed ID: 8239673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroanatomical sites of action of 5-HT3 receptor agonist and antagonists for alteration of aversive behaviour in the mouse.
    Costall B; Kelly ME; Naylor RJ; Onaivi ES; Tyers MB
    Br J Pharmacol; 1989 Feb; 96(2):325-32. PubMed ID: 2522335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties.
    Blackburn TP; Baxter GS; Kennett GA; King FD; Piper DC; Sanger GJ; Thomas DR; Upton N; Wood MD
    Psychopharmacology (Berl); 1993; 110(3):257-64. PubMed ID: 7831418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride.
    Cohen ML; Bloomquist W; Gidda JS; Lacefield W
    J Pharmacol Exp Ther; 1989 Jan; 248(1):197-201. PubMed ID: 2521513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of various 5-HT3 receptor antagonists, granisetron, ondansetron, ramosetron and azasetron on serotonin (5-HT) release from the ferret isolated ileum.
    Endo T; Minami M; Kitamura N; Teramoto Y; Ogawa T; Nemoto M; Hamaue N; Hirafuji M; Yasuda E; Blower PR
    Res Commun Mol Pathol Pharmacol; 1999; 104(2):145-55. PubMed ID: 10634307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterisation of the non-5-HT3 high-affinity 'R' binding site for (R)-zacopride in brain and other tissues.
    Kidd FJ; Levy JC; Nielsen M; Hamon M; Gozlan H
    Eur J Pharmacol; 1993 Sep; 247(1):45-56. PubMed ID: 8258360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of the 5-HT3 receptor antagonist, RS-42358-197, in animal models of anxiety.
    Costall B; Domeney AM; Kelly ME; Tomkins DM; Naylor RJ; Wong EH; Smith WL; Whiting RL; Eglen RM
    Eur J Pharmacol; 1993 Mar; 234(1):91-9. PubMed ID: 8097165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice.
    Kilfoil T; Michel A; Montgomery D; Whiting RL
    Neuropharmacology; 1989 Sep; 28(9):901-5. PubMed ID: 2572995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.